Hennion & Walsh Asset Management Inc. Purchases 29,545 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Hennion & Walsh Asset Management Inc. raised its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 25.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 145,599 shares of the company's stock after purchasing an additional 29,545 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.30% of Mirum Pharmaceuticals worth $6,021,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Lord Abbett & CO. LLC bought a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $28,913,000. Geode Capital Management LLC raised its holdings in Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company's stock valued at $36,519,000 after acquiring an additional 29,017 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in shares of Mirum Pharmaceuticals by 1.2% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 6,570,392 shares of the company's stock worth $256,245,000 after acquiring an additional 75,000 shares during the period. Barclays PLC grew its holdings in shares of Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company's stock worth $9,592,000 after purchasing an additional 10,824 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Mirum Pharmaceuticals in the third quarter valued at $215,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on MIRM shares. Leerink Partners lifted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Citigroup lifted their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. HC Wainwright reissued a "buy" rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Mirum Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $57.10.

Insider Buying and Selling

In related news, CEO Christopher Peetz sold 7,489 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the sale, the chief executive officer now owns 119,359 shares of the company's stock, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jolanda Howe sold 2,500 shares of the company's stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the transaction, the senior vice president now directly owns 2,426 shares in the company, valued at approximately $114,264.60. This represents a 50.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,737 shares of company stock worth $556,098 in the last 90 days. Corporate insiders own 22.87% of the company's stock.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM traded down $0.50 during trading on Thursday, reaching $45.83. The stock had a trading volume of 499,309 shares, compared to its average volume of 499,071. The stock has a market capitalization of $2.20 billion, a PE ratio of -22.69 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $48.89. The business's 50-day moving average price is $43.18 and its 200 day moving average price is $40.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business's revenue for the quarter was up 89.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.57) EPS. As a group, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.